Constellation Pharmaceuticals (Cambridge, MA) a development-stage biopharma focused on epigenetic therapeutic development in the field of oncology, closed a $17.2M Series B financing. Participants include Altitude Life Science Ventures, Third Rock Ventures, The Column Group and Venrock.